Secondary outcomes – Page 28 – Communicable Diseases Research

The safety and effectiveness of rehabilitation exercises on COVID-19 patients A protocol for systematic review and meta-analysis

6600

Published on 2020-07-312022-10-30
Journal: Medicine [Category] COVID-19, SARS,

Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study

경증/일반 COVID-19 감염에서 클로로퀸 대 로피나비르/리토나비르의 효능: 전향적, 공개 표지, 다기관, 무작위 대조 임상 연구

Study Protocol

Published on 2020-07-082022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] adage calculated caused Chain Reaction China Chinese Chloroquine Chloroquine phosphate clinical clinical recovery clinical study Comparisons completion control group COVID-19 COVID-19 infection drugs effective antiviral treatment Efficacy and safety eligible experiment fluorescent Follow-up follow-up period help hospitals IMPROVE include Infection Lopinavir Lopinavir/ritonavir multicenter negativity normal temperature Open-label outbreak participant Patient patients with COVID-19 performed phosphate plan polymerase chain polymerase chain reaction Primary outcome Randomized Randomized controlled clinical study Randomly Recovery time registry reverse transcription Ritonavir RT-PCR Safe SARS-CoV-2 secondary outcome Secondary outcomes Serious Adverse Event Serious Adverse Events statistical significance level temperature tested therapeutic potential therapy throat-swab treat Treatment treatment period Trial two-sided test two-sided tests with COVID-19
[DOI] 10.1186/s13063-020-04478-w PMC 바로가기 [Article Type] Study Protocol

CytoResc – “CytoSorb” Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial

CytoResc – COVID-19 사이토카인 폭풍을 겪고 있는 중환자를 위한 "CytoSorb" 구조: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-06-262022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 24 hour 24 hours Acute kidney injury Acute respiratory failure Administered Analysis Antibiotics arterial arterial pressure Bacterial Berlin blinded Blinding block blocks Blood C-reactive protein C-reactive protein (CRP catecholamine cause center Chain Reaction Charité clinical Clinical course Clinical practice clinical trials clinically clinician comparator concentrations condition conducted contraindication COVID-19 COVID-19 patient COVID-19 patients Critical care Critically ill critically ill COVID-19 patients Critically ill patient critically ill patients cytokine Cytokine storm Cytokines Cytosorb CytoSorb® data set death defined dissemination dose element elevated Endpoint extracorporeal cytokine elimination feasibility Filter Formal Germany Hemodynamics hospital discharge Hospitalization hospitalized patient hospitalized patients hyperinflammation Hyperinflammatory ICU-treatment ICUs IIb IL-6 IMPROVE Inc. Inclusion inclusion criteria indication intensive care unit intensive care units interleukin interleukin-6 intervention effect mean arterial pressure mechanical ventilation molecular weight Mortality multicenter New Norepinephrine number objective observational study occur Open-label other conditions outcome parallel group participant Patient patients PCR PCT performed phase pilot study polymerase chain polymerase chain reaction polystyrene positive pressure Prevent primary endpoint procalcitonin Proinflammatory cytokine proinflammatory cytokines protocol randomization Randomized Randomized controlled trial reason for receive recruited reducing Registered registry renal replacement therapy replacement therapy rescue Respiratory failure Safety Safety assessment Sample size SARS-CoV-2 secondary Secondary outcomes Shock shown Standard of care statistician status stratified Study design Study protocol Suspected therapy toxin Treatment Trial Trial registration USA vasoplegic shock Vasopressor vasopressors website
[DOI] 10.1186/s13063-020-04501-0 PMC 바로가기 [Article Type] Letter

A Double Triage and Telemedicine Protocol to Optimize Infection Control in an Emergency Department in Taiwan During the COVID-19 Pandemic: Retrospective Feasibility Study

Original Paper

Published on 2020-06-232022-10-30
Journal: Journal of Medical Internet Research [Category] COVID-19, SARS,

Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)

중증 COVID-19 환자를 치료하기 위한 동종 인간 치수 줄기세포의 안전성 및 효능 평가: 무작위 대조 시험(I/II상)을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-06-122022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 Acidic Adenovirus Admission AIDS Alanine alanine aminotransferase albumin alkaline phosphatase Allogeneic allogeneic human dental pulp stem cells amyloid Analysis anion gap Arm ratio aspartate Aspartate aminotransferase average B lymphocyte basophils Before menopause Bilirubin blind blinded Block randomization method Blood blood cell Blood cells blood pressure Blood routine C-reactive protein calcium carbon dioxide Care CAST caused Cell cell suspension change chest X-ray Child Pugh score chlorine cholesterol cholinesterase CLARITY clinical Clinical improvement clinical trial coded Coefficient of variation color commenced comparator computer Concentration Consent consent form Continuous renal replacement therapy control group control groups COVID-19 COVID-19; randomised controlled trial; protocol; human dental pulp stem cells; dental stem cell banking COVID-2019 creatine creatine kinase creatinine criteria crystal Cytokines cytomegalovirus cytomegalovirus CMV-IgG cytomegalovirus CMV-IgM Definition dental pulp dental pulp stem cells description detect Diastolic blood pressure direct bilirubin discharge disease dissemination distress distribution DPSCs ECMO Efficacy element enrolled eosinophil eosinophils epithelial cells estimated glomerular filtration rate Estrogen examined excluded exclusion criteria experimental group fat globules Female patients female subject filtration rate Final flow cytometry follow-up period fungi fungus Globulin glomerular filtration rate Glucose GRADE Grade 1 grade 3 Grade 5 granulocyte HBcAb HBeAb HBeAg HBsAb HBsAg hDPSCs Health Organization heart rate hematocrit Hemodialysis hemoglobin hepatitis B hepatitis C HFNC high density lipoprotein hospitalised patient Hospitalised patients Hospitalization Hospitalized human DPSC human DPSCs hypersensitive C-reactive protein hypoxia Identifier IgA IgG IgM Il -10 IL-1 IL-1 β IL-2 IL-4 IL-6 immune Immunoglobulin Immunological testing improvement IMV inclusion criteria Infectious disease Influenza Influenza virus informed consent form injection Injections intensive care intensive care unit Intravenous injection Invasive mechanical ventilation investigator investigators ITN-γ ketone ketone bodies Kidney function Kidney function tests Killer cell Laboratory laboratory examinations Lactate lactate dehydrogenase lactating women leukocyte leukocyte enzymes lipoprotein lipoprotein A lipoprotein cholesterol low density lipoprotein lung lesion lung lesions lymphocyte Lymphocytes Macrophage Magnesium Medical care Menopause Monocytes mononuclear cell mononuclear cells nasal nasal catheter natural killer natural killer cell neutrophil Neutrophils nitrite NIV Non-invasive non-invasive mechanical ventilation non-squamous epithelial cell non-squamous epithelial cells nucleic acid nucleic acid test number objective observation occult occult blood Other Other condition outcome oxygen oxygen saturation parallel group parasites partial pressure participant Patient penetration performed Peripheral blood Peritoneal dialysis phase phenotype phosphatase phosphorus Placebo placebo-controlled Platelet Platelet count platelet distribution width Platelets Potassium prealbumin pregnancy test pregnant pressure Primary outcome Protein protocol random randomisation randomization Randomized Randomized controlled trial receive receiving recruitment red blood cell red blood cells renal renal insufficiency renal replacement therapy Renmin Hospital replacement therapy required researcher respiratory respiratory distress respiratory infection respiratory rate Safety Saline saline solution Sample size SARS-CoV-2 secondary Secondary outcomes serious COVID-19 serum serum amyloid severe liver condition severe pneumonia single-cell analyses sodium specific gravity Standard deviation status stem cell study period Study protocol sugar syphilis Systolic blood pressure T lymphocyte Th1 cytokine Th1 cytokines Th2 cytokine Th2 cytokines therapeutic effect therapeutic effects time TNF-a Total total bilirubin Total cholesterol total protein traits Transferrin treat Treatment treatment for COVID-19 triacylglycerol Trial triple blinded TTCI Tuberculosis Twenty participant Twenty participants university urea uric acid Urine urobilinogen Variation Version vital signs Volume website White blood cells with HIV within 6 months women World Health Organization Wuhan γ-glutamyl transferase
[DOI] 10.1186/s13063-020-04380-5 PMC 바로가기 [Article Type] Letter

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 active malignancy acute respiratory distress syndrome Administered administration age approval approved ARDS assessment automated Berlin blinded Cell cell suspension cellular changes in chronic liver disease class clinical Clinical diagnosis Clinical outcome clinical outcomes clinical trial comparator Compliance conducted control group Controlled trial COVID 19 COVID-19 COVID-19 pandemic declined defined described determine diagnosis of COVID-19 dissemination Donor Dose escalation driving Effect Efficacy element eligible Elizabeth enrolled ethics committee EudraCT excluded facilitate failure fixed dose hospital ICU incidence Inclusion increase in index individual information infusion intensive care unit Intervention Invasive mechanical ventilation investigator King’s College London London Mesenchymal stem cells Mesenchymal stromal cells MHRA moderate Mortality MSC MSCs NIHR number objective open label Other outcome pandemic PaO participant Patient patient population patients with ARDS PCR test PF ratio Phase 1 Phase 2 Placebo placebo-controlled protocol protocol amendment Public randomised randomised controlled trial REC receiving recruited recruitment repair reported Research respiratory Resuscitation Sample size secondary Secondary objective Secondary outcomes Serious Adverse Events severe ARDS single intravenous infusion SOFA solution Standard steering committee stratified stromal cell Study protocol Therapeutics therapy trauma Treatment Trial triple blinded Trust umbilical United Kingdom university Venous Thromboembolism Ventilation verbal Volume web-based randomisation system website WHO Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter

Psychological intervention on COVID-19 A protocol for systematic review and meta-analysis

4900

Published on 2020-05-222022-10-30
Journal: Medicine [Category] COVID-19, MERS,

[키워드] 95% confidence interval Admission adverse events calculated change Chinese CIs clinical clinical heterogeneity Cochrane Library cough COVID-19 database Dyspnea effective Effectiveness Effects Efficiency Evidence expressed GAD-7 Hamilton Anxiety Scale independent Infrastructure Intervention journal literature mean difference Meta-analysis Mild Non-invasive Novel coronavirus infection outcomes Patient PHQ-9 physical positive Primary outcomes protocol psychological condition Psychological intervention random effect model randomised controlled trial registry reported requiring supplemental oxygen researcher risk RT-PCR scale searched Secondary outcomes SMD standardized mean difference suggested systematic review time Treatment upper respiratory tract used to evaluate Web of Science WHO
[DOI] 10.1097/MD.0000000000020335 PMC 바로가기 [Article Type] 4900

COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial

DEXamethasone(CoDEX)으로 치료된 COVID-19 관련 ARDS: 무작위 시험에 대한 연구 설계 및 근거

Original Article

Published on 2020-01-012022-08-13
Journal: Revista Brasileira de Terapia Intensiva [Category] 임상,

[키워드] 350 patient 350 patients 48 hour 48 hours 6-level ordinal scale acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Adrenal cortex hormones Adult patients all-cause mortality rate all-cause mortality rates assessment Berlin criteria caused clinical status clinical trial Control control group Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 - COVID-19 Corticosteroid Corticosteroides Corticosteroids COVID-19 COVID-19-associated ARDS Cuidados críticos days alive defined develop Dexametasona Dexamethasone dexamethasone 10mg IV dexamethasone 20mg intravenous early-onset Effectiveness Eligible patients evaluate evaluated failure followed by group hospitalized patient hospitalized patients Infection intensive care intervention group intravenous Invasive mechanical ventilation less mechanical ventilation mechanical ventilation duration moderate mortality rates multicenter Non-COVID-19 non-COVID-19 acute respiratory distress syndrome objective occur once daily Open-label Ordinal Scale outcome pandemic Patient patients with moderate Pneumonia Pragmatic Primary outcome randomization Randomized randomized trial Randomly receive respiratory respiratory compromise respiratory distress Respiratory distress syndrome Respiratory distress syndrome, adult Síndrome do desconforto respiratório do adulto SARS-CoV-2 SARS-COV-2 infection score secondary Secondary outcomes severe acute respiratory syndrome Coronavirus Spread standard treatment stratified Study design syndrome treated Trial unit discharge ventilator-free day Ventilator-free days Viral Viral pneumonia
[DOI] 10.5935/0103-507X.20200063 PMC 바로가기 [Article Type] Original Article

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

항레트로바이러스 요법(REALITY)을 시작하는 아프리카의 심각한 면역 저하 HIV 감염 개인의 사망률에 대한 즉시 사용 가능한 보충 식품의 효과: 공개, 병렬 그룹, 무작위 대조 시험

Article

Published on 2018-04-102022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] 1:1 95% CI adverse event adverse events age analysed anti-infection Antiretroviral therapy ART assigned block size BMI body-mass body-mass index both groups CD4 cell Cell changes in children clinic visit Clinic visits computer-generated database Department development died Dispensing Effect eight Eligible participants Evidence evidence of finding funding global health GRADE greater hazard ratio high risk HIV infection hospital hypothesise Immunocompromised in both group individual individuals infected individuals infections Intention intention to treat Interaction ISRCTN ISRCTN registry Kenya log-rank Medical Research Council medication micronutrients Mortality no evidence of nutritional status Older Open-label outcome parallel-group participant Participants peanut per day Policy present Primary outcome Prophylaxis raltegravir randomisation randomised controlled trial Randomly ready-to-use therapeutic food reducing Registered reported Safety secondary Secondary outcomes Serious Adverse Event Serious Adverse Events significantly stratified sub-Saharan Africa Symptom Trial Uganda vital status weight weight gain Wellcome Trust would increase Z score Zimbabwe
[DOI] 10.1016/S2352-3018(18)30038-9 PMC 바로가기 [Article Type] Article

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

HIV-1에 감염된 건강한 성인에서 후보 결핵 백신 MVA85A의 안전성, 면역원성 및 효능: 무작위, 위약 대조, 2상 시험

Articles

Published on 2015-03-012022-09-06
Journal: The Lancet. Respiratory Medicine [Category] Communicable Disease,

[키워드] 1:1 95% CI absence active tuberculosis adverse event Antigen antigen 85A antigen 85A-specific T-cell response antiretroviral Antiretroviral therapy assigned assist baseline baseline CD4 block blocks booster Cape CD4 count CD4 counts Cell clinical defined detect detectable Developing disease double-blind effective Efficacy eligible Eligible participants enrolled enrolment European Evidence evidence of expressing finding first vaccination foundation funding gold greater Group allocation had no healthy HIV-1 HIV-1 infection immunogenic immunogenicity include increased risk Infection injection intradermal injections investigators isoniazid isoniazid prophylaxis Laboratory latent tuberculosis latent tuberculosis infection M tuberculosis Measures Melinda Gate Melinda Gates modified vaccinia virus MVA85A Mycobacterium tuberculosis nine no evidence of Nurses occurred outcome participant partnership peaked per-protocol analysis per-protocol population Phase 2 phase 2 trial Placebo placebo group placebo-controlled positive Potential Prophylaxis protocol QuantiFERON QuantiFERON-TB Gold In-Tube randomisation randomised Randomly receive receiving Registered reported Safe Safety safety analysis second vaccination secondary Secondary outcomes sequence Serious Adverse Event Serious Adverse Events significant increase South Africa stratified subset T-cell Response the placebo group therapy town Treatment Trial Tuberculosis tuberculosis disease tuberculosis vaccine undetectable vaccination Vaccine vaccine efficacy vaccine-induced immune response Viral Viral load Wellcome Trust were assessed
[DOI] 10.1016/S2213-2600(15)00037-5 PMC 바로가기 [Article Type] Articles